His findings demonstrated that metformin inhibited the overexpression of HER2 (erbB-2) oncoprotein in human BC cells by blocking the mammalian target of rapamycin complex 1 (mTORC1) effector p70S6K1 (Vazquez-Martin et al., 2009). Here, RPS6KB1 is linked to breast cancer.